Daewoong Pharmaceutical marked the 10th anniversary of the launch of its botulinum toxin product Nabota by presenting an innovative vision centered on achieving 500 billion KRW in sales by 2030.
On the 20th, Park Sung-soo, CEO of Daewoong Pharmaceutical, is presenting at the Deep Symposium held at Dragon City Hotel in Yongsan-gu, Seoul. [Photo by Daewoong Pharmaceutical]
Daewoong Pharmaceutical announced on the 25th that it held the ‘Nabota Master Class’ from the 20th to the 23rd at the Dragon City Hotel in Yongsan-gu, Seoul. On the first day, at the DEEP Symposium held to celebrate Nabota’s 10th anniversary, Daewoong Pharmaceutical unveiled the 'Nabota 2030 Vision' and hosted discussions on global toxin trends and the future. Nabota is a botulinum toxin formulation independently developed by Daewoong Pharmaceutical and launched in 2014. It has continued its global expansion, including obtaining approval from the U.S. Food and Drug Administration (FDA) in 2019.
Park Sung-soo, CEO of Daewoong Pharmaceutical, diagnosed the trends and future of the global toxin market under the theme ‘The Future of Toxin and Nabota’ at the symposium and revealed Nabota’s mid- to long-term strategies. Park said, “The aesthetic medical market is the sector with the highest growth potential within the global healthcare industry,” adding, “The current global botulinum toxin market is worth 8 trillion KRW and is expected to nearly double by 2030.” He also predicted, “Innovation in various fields such as new therapeutic indications and new product development will drive the growth of the next-generation botulinum toxin market.”
About 400 medical professionals from the global aesthetic and plastic surgery fields attended the symposium to hear about Daewoong Pharmaceutical’s future vision for Nabota and discuss the latest procedures and trends in botulinum toxin formulations. Louis Abella, CMO of Evolus, Daewoong’s overseas strategic partner, said, “In comparative clinical trials among global competing products, Jeuveau (Nabota’s U.S. brand name) demonstrates superiority in accuracy, durability, and patient satisfaction,” adding, “Jeuveau’s quality competitiveness ultimately lies in its excellent manufacturing process, and the strong partnership between Evolus and Daewoong has enabled rapid growth in the U.S.”
Innovation continued with Nabota’s applications in areas such as hair loss. Professor Park Byung-chul of Dankook University Hospital’s Dermatology Department presented research on male pattern hair loss treatment using Nabota. Professor Park said, “In a 24-week clinical trial involving 18 adult males, hair loss decreased and hair volume increased,” adding, “Nabota alone is sufficiently effective for hair loss, but its effect is enhanced when combined with the oral drug finasteride.”
Nabota is also advancing into the therapeutic market. The Phase 2 clinical trial for chronic migraine currently underway in the U.S. is expected to release topline results in the second quarter of this year, with Phase 3 trials for episodic and chronic migraine planned for next year. Clinical trials for indications such as gastroparesis and post-traumatic stress disorder (PTSD) are also being prepared. Through these efforts, Daewoong plans to enter the U.S. therapeutic market by 2028.
Park Sung-soo, CEO of Daewoong Pharmaceutical, stated, “Botulinum toxin is an attractive market with great potential in both aesthetic and therapeutic fields,” and added, “We will grow Nabota into a global blockbuster toxin by expanding the number of countries where it is launched, increasing supply volume, and entering advanced therapeutic markets.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
